Despite significant advances in the treatment of multiple myeloma which had led to
unprecedented rates of response and survival, patients still relapse, and cure remains …

Despite substantial advances in anti-myeloma treatments, early recurrence and death
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …

Background In patients with newly diagnosed multiple myeloma, the effect of adding
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib …

PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …

PURPOSE The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide,
and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) …

The historical lack of preclinical models reflecting the genetic heterogeneity of multiple
myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this …

Few prospective studies have examined posttransplant chimeric antigen receptor (CAR) T
cell infusion as candidates for front‐line consolidation therapy for high‐risk multiple …

Detecting persistent minimal residual disease (MRD) allows the identification of patients with
an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after …

High-risk (HR) cytogenetics are associated with poor outcomes in newly diagnosed multiple
myeloma (NDMM), and dedicated studies should address this difficult-to-treat population …

Intratumor heterogeneity as a clinical challenge becomes most evident after several
treatment lines, when multidrug-resistant subclones accumulate. To address this challenge …